Use of Cilostazol, a Novel Antiplatelet Agent, in a Post-Palmaz-Schatz Stenting Regimen
Section snippets
Methods
The study protocol was approved by our institute's ethics committee and was in accord with the principles of the Declaration of Helsinki. The possible risks and benefits of the new medication protocol were fully explained to each patient and his/her family, and written informed consent was obtained before the patients participated in the study.
Patient and Lesion Characteristics
Implantation of Palmaz-Schatz stents was attempted in 89 lesions of 76 patients. The stent was successfully deployed in 88 lesions of 75 patients. In 1 patient, a stent mounted on a Viva balloon failed to successfully cross the predilated stenosis located at the orifice of the left anterior descending artery. In 4 lesions of 4 patients, the stenting result was considered suboptimal because of dissection at the distal edge of the stent. They were also treated with aspirin and cilostazol after
Discussion
The results of this nonrandomized prospective study demonstrated that cilostazol is potentially useful as part of an antiplatelet regimen after Palmaz-Schatz stent implantation.
References (20)
- et al.
Role of platelet activation and fibrin formation in thrombogenesis
J Am Coll Cardiol
(1986) - et al.
Subacute stent thrombosis and the anticoagulation controversy: changes in drug therapy, operator technique, and the impact of intravascular ultrasound
Am J Cardiol
(1996) - et al.
A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease
N Engl J Med
(1994) - et al.
A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease
N Engl J Med
(1994) - et al.
Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound
Circulation
(1995) - et al.
Intracoronary stenting without coumadin: one-month results of a French multicenter study
Cathet Cardiovasc Diagn
(1995) Advances in post stenting medication protocol
J Invas Cardiol
(1995)- et al.
A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
N Engl J Med
(1996) - et al.
Is ticlopidine a necessary component of antiplatelet regimens following coronary artery stenting (abstr)
J Am Coll Cardiol
(1996) - et al.
Studies on 2-oxoquinolinone derivatives as blood platelet aggregation inhibitors IV. Synthesis and biological activity of metabolites of 6-[4-(1-cyclohexyl-1H-5-tetrazolyl) butoxyl]-2-oxo-1, 2, 3, 4-tetrahydroquinolinone (OPC—13013)
Chem Pharm Bull (Tokyo)
(1985)